SEARCH

SEARCH BY CITATION

References

  • Anderson, K., Lutz, C., van Delft, F.W., Bateman, C.M., Guo, Y., Colman, S.M., Kempski, H., Moorman, A.V., Titley, I., Swansbury, J., Kearney, L., Enver, T. & Greaves, M. (2011) Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature, 469, 356361.
  • Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma Intergroupe Francais du Myelome. New England Journal of Medicine, 335, 9197.
  • Attal, M., Harousseau, J.L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.J., Grosbois, B. & Bataille, R. (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 349, 24952502.
  • Barlogie, B., Kyle, R.A., Anderson, K.C., Greipp, P.R., Lazarus, H.M., Hurd, D.D., McCoy, J., Moore, D.F. Jr., Dakhil, S.R., Lanier, K.S., Chapman, R.A., Cromer, J.N., Salmon, S.E., Durie, B. & Crowley, J.C. (2006) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. Journal of Clinical Oncology, 24, 929936.
  • Bensinger, W.I., Buckner, C.D., Anasetti, C., Clift, R., Storb, R., Barnett, T., Chauncey, T., Shulman, H. & Appelbaum, F.R. (1996) Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood, 88, 27872793.
  • Bensinger, W.I., Maloney, D. & Storb, R. (2001) Allogeneic hematopoietic cell transplantation for multiple myeloma. Seminars in Hematology, 38, 243249.
  • Bird, J.M., Russell, N.H. & Samson, D. (1993) Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivors. Bone Marrow Transplantation, 12, 651654.
  • Bjorkstrand, B.B., Ljungman, P., Svensson, H., Hermans, J., Alegre, A., Apperley, J., Blade, J., Carlson, K., Cavo, M., Ferrant, A., Goldstone, A.H., de Laurenzi, A., Majolino, I., Marcus, R., Prentice, H.G., Remes, K., Samson, D., Sureda, A., Verdonck, L.F., Volin, L. & Gahrton, G. (1996) Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood, 88, 47114718.
  • Bjorkstrand, B., Iacobelli, S., Hegenbart, U., Gruber, A., Greinix, H.T., Volin, L., Narni, F., Musto, P., Beksac, M., Bosi, A., Niederwieser, D. & Gahrton, G. (2009) Autologus stem cell transplantation (ASCT) versus ASCT followed by reduced-intensity conditioning (RIC) allogeneic SCT with identical sibling donor in previously untreated multiple myeloma (MM): a prospective controlled trial by the EBMT. Bone Marrow Transplantation, 43, s31.
  • Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 11151123.
  • Cavo, M., Tosi, P., Zamagni, E., Cellini, C., Tacchetti, P., Patriarca, F., Di Raimondo, F., Volpe, E., Ronconi, S., Cangini, D., Narni, F., Carubelli, A., Masini, L., Catalano, L., Fiacchini, M., de Vivo, A., Gozzetti, A., Lazzaro, A., Tura, S. & Baccarani, M. (2007) Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: bologna 96 clinical study. Journal of Clinical Oncology, 25, 24342441.
  • Child, J.A., Morgan, G.J., Davies, F.E., Owen, R.G., Bell, S.E., Hawkins, K., Brown, J., Drayson, M.T. & Selby, P.J. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New England Journal of Medicine, 348, 18751883.
  • Corradini, P., Voena, C., Tarella, C., Astolfi, M., Ladetto, M., Palumbo, A., Van Lint, M.T., Bacigalupo, A., Santoro, A., Musso, M., Majolino, I., Boccadoro, M. & Pileri, A. (1999) Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. Journal of Clinical Oncology, 17, 208215.
  • Corradini, P., Cavo, M., Lokhorst, H., Martinelli, G., Terragna, C., Majolino, I., Valagussa, P., Boccadoro, M., Samson, D., Bacigalupo, A., Russell, N., Montefusco, V., Voena, C. & Gahrton, G. (2003) Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood, 102, 19271929.
  • Crawley, C., Lalancette, M., Szydlo, R., Gilleece, M., Peggs, K., Mackinnon, S., Juliusson, G., Ahlberg, L., Nagler, A., Shimoni, A., Sureda, A., Boiron, J.M., Einsele, H., Chopra, R., Carella, A., Cavenagh, J., Gratwohl, A., Garban, F., Zander, A., Bjorkstrand, B., Niederwieser, D., Gahrton, G. & Apperley, J.F. (2005) Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood, 105, 45324539.
  • Crawley, C., Iacobelli, S., Bjorkstrand, B., Apperley, J.F., Niederwieser, D. & Gahrton, G. (2007) Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood, 109, 35883594.
  • Gahrton, G., Svensson, H., Cavo, M., Apperly, J., Bacigalupo, A., Bjorkstrand, B., Blade, J., Cornelissen, J., de Laurenzi, A., Facon, T., Ljungman, P., Michallet, M., Niederwieser, D., Powles, R., Reiffers, J., Russell, N.H., Samson, D., Schaefer, U.W., Schattenberg, A., Tura, S., Verdonck, L.F., Vernant, J.P., Willemze, R. & Volin, L. (2001) Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centres. British Journal of Haematology, 113, 209216.
  • Jan, M. & Majeti, R. (2012) Clonal evolution of acute leukemia genomes Oncogene. Epub ahead of print, 2012, 48. doi: 10.1038/onc
  • Kapoor, P., Fonseca, R., Rajkumar, S.V., Sinha, S., Gertz, M.A., Stewart, A.K., Bergsagel, P.L., Lacy, M.Q., Dingli, D.D., Ketterling, R.P., Buadi, F., Kyle, R.A., Witzig, T.E., Greipp, P.R., Dispenzieri, A. & Kumar, S. (2010) Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clinic Proceedings, 85, 532537.
  • Keats, J.J., Chesi, M., Egan, J.B., Garbitt, V.M., Palmer, S.E., Braggio, E., Van Wier, S., Blackburn, P.R., Baker, A.S., Dispenzieri, A., Kumar, S., Rajkumar, S.V., Carpten, J.D., Barrett, M., Fonseca, R., Stewart, A.K. & Bergsagel, P.L. (2012) Clonal competition with alternating dominance in multiple myeloma. Blood, 120, 10671076.
  • Kneppers, E., van der Holt, B., Kersten, M.-J., Zweegman, S., Meijer, E., Huls, G., Cornelissen, J.J., Janssen, J.J., Huisman, C., Cornelisse, P.B., Bruijnen, C.P., Emmelot, M., Sonneveld, P., Lokhorst, H.M., Mutis, T. & Minnema, M.C. (2011) Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood, 118, 24132419.
  • Kroger, N., Perez-Simon, J.A., Myint, H., Klingemann, H., Shimoni, A., Nagler, A., Martino, R., Alegre, A., Tomas, J.F., Schwerdtfeger, R., Kiehl, M., Fauser, A., Sayer, H.G., Leon, A., Beyer, J., Zabelina, T., Ayuk, F., San Miguel, J.F., Brand, R. & Zander, A.R. (2004) Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation, 10, 698708.
  • Lokhorst, H.M., van der Holt, B., Cornelissen, J.J., Kersten, M.J., van Oers, M., Raymakers, R., Minnema, M.C., Zweegman, S., Janssen, J.J., Zijlmans, M., Bos, G., Schaap, N., Wittebol, S., de Weerdt, O., Ammerlaan, R. & Sonneveld, P. (2012) Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood, 119, 62196225.
  • Maloney, D.G., Molina, A.J., Sahebi, F., Stockerl-Goldstein, K.E., Sandmaier, B.M., Bensinger, W., Storer, B., Hegenbart, U., Somlo, G., Chauncey, T., Bruno, B., Appelbaum, F.R., Blume, K.G., Forman, S.J., McSweeney, P. & Storb, R. (2003) Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood, 102, 34473454.
  • Mullighan, C.G., Phillips, L.A., Su, X., Ma, J., Miller, C.B., Shurtleff, S.A. & Downing, J.R. (2008) Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science, 322, 13771380.
  • Munshi, N.C., Anderson, K.C., Bergsagel, P.L., Shaughnessy, J., Palumbo, A., Durie, B., Fonseca, R., Stewart, A.K., Harousseau, J.-L., Dimopoulos, M., Jagannath, S., Hajek, R., Sezer, O., Kyle, R., Sonneveld, P., Cavo, M., Rajkumar, S.V., San Miguel, J., Crowley, J. & Avet-Loiseau, H., on behalf of the International Myeloma Workshop Consensus Panel 2. (2011) Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood, 117, 46964700.
  • Rotta, M., Storer, B.E., Sahebi, F., Shizuru, J.A., Bruno, B., Lange, T., Agura, E.D., McSweeney, P.A., Pulsipher, M.A., Hari, P., Maziarz, R.T., Chauncey, T.R., Appelbaum, F.R., Sorror, M.L., Bensinger, W., Sandmaier, B.M., Storb, R.F. & Maloney, D.G. (2009) Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood, 113, 33833391.
  • Shimoni, A., Hardan, I., Ayuk, F., Schilling, G., Atanackovic, D., Zeller, W., Yerushalmi, R., Zander, A.R., Kroger, N. & Nagler, A. (2010) Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up. Cancer, 116, 36213630.
  • Tricot, G., Vesole, D.H., Jagannath, S., Hilton, J., Munshi, N. & Barlogie, B. (1996) Graft-versus-myeloma effect: proof of principle. Blood, 87, 11961198.